NIA-AA Symposium — Enabling Precision Medicine for Alzheimer’s Disease Through Open Science

Thursday, July 25, 2024 | 1-5:30 p.m.
Friday, July 26, 2024 | 8 a.m. - noon
Marriott (Grand Ballrooms G,K,L) — Philadelphia, USA
All times are in Eastern Standard Time
In-person attendance only

Overview
The 7th Annual NIA-AA Symposium — Enabling Precision Medicine for Alzheimer’s Disease Through Open Science will feature an array of NIA-supported translational research programs that employ precision medicine principles and open-science practices which aim to:

- Understand the complex and heterogeneous etiology of Alzheimer’s disease (AD) and AD-related dementias (ADRD)
- Develop the next generation animal models for AD
- Identify and validate new disease-relevant targets and biomarkers
- Advance novel targets into drug discovery
- Bring precision medicine approaches to therapy development

Organizing Committee

NIA
- Suzana Petanceska
- Lorenzo Refolo
- Laurie Ryan
- Erika Tarver

Alzheimer’s Association
- Rebecca Edelmayer
- Ozama Ismail
- Claire Sexton

Target Audience
Academic, biotech and pharmaceutical industry researchers with interest in target and biomarker discovery, preclinical and clinical drug development; computational biologists; data scientists; and open science advocates.
Registration

The program for this pre-conference was jointly developed by the National Institute on Aging and the Alzheimer’s Association. Registration for this pre-conference is managed and coordinated solely by the Alzheimer’s Association, and none of the registration fees will be shared with the National Institute on Aging. If you have any questions regarding registration, please contact the Alzheimer’s Association.

Preconferences require a separate registration in addition to AAIC full conference registration, or they may be registered as stand-alone events.

Agenda, Day 1: July 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
<th>Speakers and Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noon - 1:00 p.m.</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m. - 1:15 p.m.</td>
<td>Welcome</td>
<td>• Suzana Petanceska, National Institute on Aging (NIA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Rebecca Edelmayer, Alzheimer’s Association</td>
</tr>
</tbody>
</table>
| 1:15 p.m. - 3:15 p.m.| **Session 1**: Accelerating Medicines Partnerships® Program on Alzheimer’s Disease: Enabling a Precision Medicine Approach to Target and Biomarker Discovery | Chair: Suzana Petanceska, NIA  
• Speakers:  
  ○ Suzana Petanceska, NIA  
  ○ Laurie Ryan, NIA  
  ○ Anna Greenwood, Sage Bionetworks  
  ○ Matthias Arnold, Helmholtz University/Duke University  
  ○ Cory Funk, Institute for Systems Biology  
  ○ Minerva Carrasquillo, Mayo Clinic  
  ○ Minghui Wang, Icahn School of Medicine at Mount Sinai  
  ○ Richa Batra, Weill Cornell Medicine |
### Session 2: MODEL-AD: Building Mouse Models of Late-Onset Alzheimer's Disease as Precision Medicine Research Tools

**Chair:** Lorenzo Refolo, NIA  
**Speakers:**  
- MODEL-AD University of California, Irvine (UCI)  
  - Frank LaFerla, UCI  
  - Kim Green, UCI  
  - Vivek Swarup, UCI  
- MODEL-AD Indiana University/The Jackson Laboratory  
  - Michael Sasner, The Jackson Laboratory  
  - Greg Carter, The Jackson Laboratory  
- MODEL-AD Pre-Clinical Testing Core  
  - Stacey Rizzo, University of Pittsburgh  
  - Paul Territo, Indiana University

### Agenda, Day 2: July 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
<th>Speakers and Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. - 8:00 a.m.</td>
<td>Light Breakfast</td>
<td></td>
</tr>
</tbody>
</table>
| 8:00 a.m. - 9:30 a.m. | **Session 3: TREAT-AD:** Expanding the Drug Target Landscape and Accelerating Drug Discovery for Novel Targets | Chair: Nandini Arunkumar, NIA  
  - Speakers  
  - Emory University - Sage Bionetworks - Structural Genomics Consortium Center  
    - Greg Cary, The Jackson Laboratory  
    - Aled Edwards, Structural Genomics Consortium  |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Update</th>
<th>Speaker/Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 a.m. - 9:45 a.m.</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>9:45 a.m. - 11:15 a.m.</td>
<td><strong>Session 4:</strong> Enabling Precision Medicine for AD/ADRD: From Cohort Studies to Clinical Trials</td>
<td>Chair: Laurie Ryan, NIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Speakers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Andy Saykin, IUSM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Sid O’Bryant, University of North Texas Health Science Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Gus Jimenez-Maggiora, University of Southern California/Alzheimer’s Therapeutic Research Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td>○ Mike Rafii, University of Southern California/Alzheimer’s Therapeutic Research Institute</td>
</tr>
<tr>
<td>11:15 a.m. - 11:45 a.m.</td>
<td><strong>Update from the ADSP Phenotype Harmonization Consortium</strong></td>
<td>Speaker</td>
</tr>
<tr>
<td>Noon - 1 p.m.</td>
<td><strong>Lunch</strong></td>
<td>• Timothy J. Hohman, Vanderbilt University</td>
</tr>
</tbody>
</table>